Evaluation of the adverse effects of iomeprol.
The new non-ionic contrast medium iomeprol (Iomeron) 150/200/250/300/350/400 was tested in a non-selected patient population (n = 4811). The aim of the clinical testing, in a very diverse range of radiographical examinations, was to evaluate its tolerance. A high percentage of the patients showed risk factors such as allergic predisposition (22.0%), cardiovascular diseases (45.3%), and kidney disease (15.1%). In addition, high doses of the contrast medium were used, depending on the radiological problem. The proportion of patients over 70 was 19.5%. Iomeprol proved to be an extremely well tolerated nonionic contrast medium. With the exception of nausea, systemic side effects occurred in less than 1% of cases.